Is PGT-A worth it?

This is genuinely contested, and you should be given the honest picture rather than a sales case. What the evidence shows: PGT-A has not been demonstrated to increase live birth rates compared with not doing it, for most patients. ASRM (2026) states it has not been shown to reduce time to successful pregnancy or increase live birth rate compared with expectant management. Why it can appear to work: success rates are often quoted per embryo transfer. If you only transfer embryos that passed testing, the per-transfer figure looks better — but cycles where no embryo passed testing have been removed from the calculation. Compare per cycle started, and the advantage largely disappears. Ask your clinic for their live birth rate per cycle started, not per transfer. Where PGT-A may genuinely help: It can shorten the path by avoiding transfers unlikely to succeed, which matters if each transfer costs you money and time. It may reduce the chance of miscarriage from chromosome abnormality, though miscarriage still occurs in a proportion of pregnancies after PGT-A. With many embryos available, it helps decide which to transfer first. Where it may harm: It costs significantly more. It requires biopsy and freezing. Embryos may be discarded that could have resulted in a healthy baby — mosaic and even some abnormal results are not always what they appear. With few embryos, testing may leave you with none to transfer. The honest summary: PGT-A gives you more information. It has not been shown to give you more babies.